Study identifies promising therapy to prevent relapses in rare neurological disease

An international study led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers as a promising option for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is a rare autoimmune neurological disorder that can cause vision loss, paralysis, and other serious complications.

The study, published in JAMA Neurology, provides new evidence to help guide treatment decisions while randomized clinical trials are underway. Two medications, tocilizumab and satralizumab, were evaluated in the study, which found that patients treated with IL-6 receptor blockers had substantially fewer relapses and a generally favorable safety profile.

Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.